Skyclarys reduces inflammation marker in adults with FA
Skyclarys (omaveloxolone) was well tolerated and associated with stable disease measures and reduced inflammation markers in adults with Friedreich’s ataxia (FA) over about six months, according to a real-world study in Italy. In particular, the treatment was associated with significantly lower levels of interleukin (IL)-6, a molecule involved…